Pheochromocytoma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Pheochromocytoma – Pipeline Review, H1 2018’, provides an overview of the Pheochromocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Pheochromocytoma

– The report reviews pipeline therapeutics for Pheochromocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pheochromocytoma therapeutics and enlists all their major and minor projects

– The report assesses Pheochromocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pheochromocytoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pheochromocytoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pheochromocytoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Exelixis Inc

Ipsen SA

Lixte Biotechnology Holdings Inc

Novartis AG

Pfizer Inc

Progenics Pharmaceuticals Inc

Tarveda Therapeutics Inc

Valeant Pharmaceuticals International Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pheochromocytoma Overview

Pheochromocytoma Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pheochromocytoma Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pheochromocytoma Companies Involved in Therapeutics Development

Exelixis Inc

Ipsen SA

Lixte Biotechnology Holdings Inc

Novartis AG

Pfizer Inc

Progenics Pharmaceuticals Inc

Tarveda Therapeutics Inc

Valeant Pharmaceuticals International Inc

Pheochromocytoma Drug Profiles

177Lu-Satoreotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iobenguane I 131 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LMP-400 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lutetium Lu 177 dotatate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metyrosine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONC-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEN-221 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pheochromocytoma Dormant Projects

Pheochromocytoma Product Development Milestones

Featured News & Press Releases

Mar 22, 2018: Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA (iobenguane I 131)

Mar 19, 2018: Progenics Pharmaceuticals Announces Presentation of AZEDRA (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society Annual Meeting

Feb 01, 2018: Progenics Pharmaceuticals Announces Presentation of AZEDRA (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

Dec 29, 2017: Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Nov 02, 2017: Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Oct 04, 2017: Data from Pivotal Phase 2b Study of Progenics’ AZEDRA (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium

Aug 31, 2017: Progenics Pharmaceuticals Presents Data from AZEDRA Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma

Aug 31, 2017: Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA

Mar 30, 2017: Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA

Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra

Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015

Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015

Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pheochromocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pheochromocytoma Pipeline by Exelixis Inc, H1 2018

Pheochromocytoma Pipeline by Ipsen SA, H1 2018

Pheochromocytoma Pipeline by Lixte Biotechnology Holdings Inc, H1 2018

Pheochromocytoma Pipeline by Novartis AG, H1 2018

Pheochromocytoma Pipeline by Pfizer Inc, H1 2018

Pheochromocytoma Pipeline by Progenics Pharmaceuticals Inc, H1 2018

Pheochromocytoma Pipeline by Tarveda Therapeutics Inc, H1 2018

Pheochromocytoma Pipeline by Valeant Pharmaceuticals International Inc, H1 2018

Pheochromocytoma Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Pheochromocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports